However, the phase 3 MORPHO trial failed to reach the primary outcome of improved relapse‐free survival (RFS) with post‐HSCT maintenance gilteritinib compared to placebo in FLT3‐ITD AML patients except in measurable residual disease (MRD) positive patients [5]. This evidence concerns the gene FLT3 and acute myeloid leukemia.